

Amendments to the Claims:

Please cancel claim 12 without prejudice.

Please amend claims 1-11 as follows.

Please add claim 14.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Use of a D- or L-tryptophanyl ester or its N-acyl derivative for producing a pharmaceutical composition for the prophylaxis and therapy of oxidative pathologic processes in degenerative diseases and/or cancer diseases~~A method for treating or preventing degenerative and/or cancer diseases caused by oxidative processes comprising the administration of a therapeutic amount of a composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative.
2. (Currently Amended) ~~Use~~The method according to claim 1 ~~or 14~~, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative is ~~the following substance~~ selected from the group consisting of:

tryptophanoctyl-ester, tryptophandodecyl-ester,
tryptophanstearyl-ester, tryptophanpalmityl-ester,
tryptophanoleyl-ester, N-acetyl-tryptophanoctyl-ester, N-
acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-
ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-
tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-
dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-
tryptophanstearyl-ester, N-dodecanoyl-tryptophanpalmityl-
ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-
tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester, N-
octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-
ester, N-stearoyl-tryptophanethyl-ester, N-palmitoyl-
tryptophanethyl-ester and N-oleoyl-tryptophanethyl-ester.

3. (Currently Amended) ~~Use~~The method according to claim 1
or 14, wherein the D- or L-tryptophanethyl-ester or its N-
acetyl derivative is selected from the group consisting of
tryptophanoctyl-ester, N-oleoyl-tryptophanethyl-ester and N-
dodecanoyl-tryptophanethyl-ester.

4. (Currently Amended) ~~Use~~The method according to any one
of claims 1 ~~to 3~~, 2 or 14 ~~for the treatment and/or~~
~~prophylaxis of~~, wherein the disease is a neurodegenerative
~~diseases~~ disease.

5. (Currently Amended) ~~Use~~The method according to claim 4, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, apoplectic fit or amyotrophic lateral sclerosis.

6. (Currently Amended) ~~Use~~The method according to any one of claims 1 ~~to 3~~, 2 or 14 ~~for the treatment and/or prophylaxis of~~, wherein the disease is of cataracts cataract.

7. (Currently Amended) ~~Use~~The method according to claim 6, wherein the cataract is Cataracta senilis, Cataracta juvenilis, Cataracta diabetica or Cataracta complicata.

8. (Currently Amended) ~~Use~~The method according to any one of claims 1 ~~to 3~~, 2 or 14 ~~for the treatment and/or prophylaxis of~~, wherein the disease is a neoplastic diseases disease.

9. (Currently Amended) ~~Use~~The method according to claim 8, wherein the neoplastic disease is selected from the group consisting of the prostatic carcinoma, the mammary carcinoma, the liver carcinoma, the kidney carcinoma, the colon carcinoma, the gastric carcinoma ~~or~~ and the lung (bronchial) carcinoma.

10. (Currently Amended) ~~Use~~The method according to any one of claims 1 ~~to 3~~, 2 or 14 ~~for the treatment and/or~~

Application No.: Not yet assigned
Preliminary Amendment dated February 27, 2004

~~prophylaxis of~~, wherein the disease is a cardiovascular
diseases disease.


11. (Currently Amended) UseThe method according to claim 10,
wherein the cardiovascular disease is arteriosclerosis or a
myocardial infarction.

12. (Canceled).

13. (Currently Amended) ~~Use for the prophylaxis and therapy
of oxidative pathologic processes in degenerative diseases
and/or cancer diseases comprising the administration of a
prophylactic or therapeutic amount of a D- or L-tryptophanyl-
ester or its N-acyl derivative according to any one of claims
1 to 3A~~ method for treating or preventing degenerative and/or
cancer diseases caused by oxidative processes comprising the
administration of a therapeutic amount of a composition
comprising a D- or L-tryptophanyl-ester or its N-acyl
derivative according to any one of claims 1, 2 or 14.

Application No.: Not yet assigned
Preliminary Amendment dated February 27, 2004

14. (New) The method according to claim 1, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative has the following formula:



wherein X is C(O)R₁, and R₁ is wherein X is C(O)R₁ or H, and R₁ is a saturated C₂-C₁₈ carbon hydrogen residue and R₂ is a saturated or unsaturated C₂-C₁₈ carbon hydrogen residue.